OMRF scientists need volunteers for the world’s first lupus prevention study.
David Key had never heard of sarcoidosis—until the rare disease stole his health.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The SMILE trial will seek to identify individuals at high risk for developing lupus and treat them before they ever transition into the disease.
Osteoarthritis is the most common form of disability in the U.S., but you might find an ally against it in the produce section.
The Scheinberg Award recognizes research excellence in the field of neurorehabiliation in MS.